Cargando…
GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients
INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymor...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552530/ https://www.ncbi.nlm.nih.gov/pubmed/34722260 http://dx.doi.org/10.3389/fonc.2021.714421 |
_version_ | 1784591393734262784 |
---|---|
author | Baba, Shahid M. Pandith, Arshad A. Shah, Zafar A. Geelani, Sajad A. Bhat, Javid R. Gul, Ayaz Guru, Sameer A. El-Serehy, Hamed A. Koul, Abid M. Mansoor, Sheikh |
author_facet | Baba, Shahid M. Pandith, Arshad A. Shah, Zafar A. Geelani, Sajad A. Bhat, Javid R. Gul, Ayaz Guru, Sameer A. El-Serehy, Hamed A. Koul, Abid M. Mansoor, Sheikh |
author_sort | Baba, Shahid M. |
collection | PubMed |
description | INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymorphisms with the etiology and therapeutic outcome of B-ALL among Kashmiri population. METHODS: A total of 300 individuals including 150 newly diagnosed B-ALL patients and an equal number of age and gender matched controls were genotyped for five GST gene polymorphisms by polymerase chain reaction–restriction fragment length polymorphism technique (PCR-RFLP) and multiplex PCR techniques. RESULTS: Higher frequency of GSTT1 (null), GSTO2-AG, and GSTO2-GG genotypes was observed in ALL cases compared to controls that associated significantly with ALL risk (GSTT1 (null:) OR = 2.93, p = 0.0001; GSTO2-AG: OR = 2.58, p = 0.01; GSTO2-GG: OR = 3.13, p = 0.01). GSTM1, GSTP1, and GSTO1 SNPs showed no significant association (p > 0.05). Combined genotype analysis revealed significant association of GSTT1 (null)/GSTM1 (null) (OR = 4.11, p = 0.011) and GSTT1 (null)/GSTP1-AG (OR = 4.93, p = 0.0003) with B-ALL susceptibility. Haplotype analysis of rs4925 and rs156697 revealed that carriers of CG haplotype had increased risk of B-ALL (p = 0.04). Kaplan–Meier plots revealed significantly inferior 3-year disease-free survival for GSTO2-GG carriers (p = 0.002). Multivariate analysis confirmed GSTO2-GG as an independent poor prognostic factor for DFS (HR = 4.5, p = 0.034). Among combined genotypes, only GSTT1 (null)/GSTP1-AG associated significantly with poorer DFS rates (p = 0.032). CONCLUSION: This study demonstrated that GSTT1 (null) individually or in combination with GSTM1(null) and GSTP1-AG genotypes associated with increased B-ALL risk. Also, rs156697 variant genotypes (AG and GG) associated with B-ALL, whereas the GG genotype of rs156697 influenced the treatment outcome. |
format | Online Article Text |
id | pubmed-8552530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85525302021-10-29 GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients Baba, Shahid M. Pandith, Arshad A. Shah, Zafar A. Geelani, Sajad A. Bhat, Javid R. Gul, Ayaz Guru, Sameer A. El-Serehy, Hamed A. Koul, Abid M. Mansoor, Sheikh Front Oncol Oncology INTRODUCTION: Glutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL). This case–control study investigated the association of GST gene polymorphisms with the etiology and therapeutic outcome of B-ALL among Kashmiri population. METHODS: A total of 300 individuals including 150 newly diagnosed B-ALL patients and an equal number of age and gender matched controls were genotyped for five GST gene polymorphisms by polymerase chain reaction–restriction fragment length polymorphism technique (PCR-RFLP) and multiplex PCR techniques. RESULTS: Higher frequency of GSTT1 (null), GSTO2-AG, and GSTO2-GG genotypes was observed in ALL cases compared to controls that associated significantly with ALL risk (GSTT1 (null:) OR = 2.93, p = 0.0001; GSTO2-AG: OR = 2.58, p = 0.01; GSTO2-GG: OR = 3.13, p = 0.01). GSTM1, GSTP1, and GSTO1 SNPs showed no significant association (p > 0.05). Combined genotype analysis revealed significant association of GSTT1 (null)/GSTM1 (null) (OR = 4.11, p = 0.011) and GSTT1 (null)/GSTP1-AG (OR = 4.93, p = 0.0003) with B-ALL susceptibility. Haplotype analysis of rs4925 and rs156697 revealed that carriers of CG haplotype had increased risk of B-ALL (p = 0.04). Kaplan–Meier plots revealed significantly inferior 3-year disease-free survival for GSTO2-GG carriers (p = 0.002). Multivariate analysis confirmed GSTO2-GG as an independent poor prognostic factor for DFS (HR = 4.5, p = 0.034). Among combined genotypes, only GSTT1 (null)/GSTP1-AG associated significantly with poorer DFS rates (p = 0.032). CONCLUSION: This study demonstrated that GSTT1 (null) individually or in combination with GSTM1(null) and GSTP1-AG genotypes associated with increased B-ALL risk. Also, rs156697 variant genotypes (AG and GG) associated with B-ALL, whereas the GG genotype of rs156697 influenced the treatment outcome. Frontiers Media S.A. 2021-10-14 /pmc/articles/PMC8552530/ /pubmed/34722260 http://dx.doi.org/10.3389/fonc.2021.714421 Text en Copyright © 2021 Baba, Pandith, Shah, Geelani, Bhat, Gul, Guru, El-Serehy, Koul and Mansoor https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Baba, Shahid M. Pandith, Arshad A. Shah, Zafar A. Geelani, Sajad A. Bhat, Javid R. Gul, Ayaz Guru, Sameer A. El-Serehy, Hamed A. Koul, Abid M. Mansoor, Sheikh GSTT1 (null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title |
GSTT1
(null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title_full |
GSTT1
(null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title_fullStr |
GSTT1
(null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title_full_unstemmed |
GSTT1
(null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title_short |
GSTT1
(null) and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients |
title_sort | gstt1
(null) and rs156697 polymorphism in gsto2 influence the risk and therapeutic outcome of b-acute lymphoblastic leukemia patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552530/ https://www.ncbi.nlm.nih.gov/pubmed/34722260 http://dx.doi.org/10.3389/fonc.2021.714421 |
work_keys_str_mv | AT babashahidm gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT panditharshada gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT shahzafara gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT geelanisajada gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT bhatjavidr gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT gulayaz gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT gurusameera gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT elserehyhameda gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT koulabidm gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients AT mansoorsheikh gstt1nullandrs156697polymorphismingsto2influencetheriskandtherapeuticoutcomeofbacutelymphoblasticleukemiapatients |